Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) EBIAT (2016 - 2025)

Historic EBIAT for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$10.6 million.

  • Aytu Biopharma's EBIAT fell 144314.72% to -$10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$25.1 million, marking a year-over-year decrease of 37811.9%. This contributed to the annual value of -$14.2 million for FY2025, which is 1048.98% up from last year.
  • Latest data reveals that Aytu Biopharma reported EBIAT of -$10.6 million as of Q4 2025, which was down 144314.72% from $2.0 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's EBIAT peaked at $4.0 million during Q1 2025, and registered a low of -$53.3 million during Q1 2022.
  • Over the past 5 years, Aytu Biopharma's median EBIAT value was -$6.9 million (recorded in 2022), while the average stood at -$10.4 million.
  • The largest annual percentage gain for Aytu Biopharma's EBIAT in the last 5 years was 23834.43% (2025), contrasted with its biggest fall of 144314.72% (2025).
  • Aytu Biopharma's EBIAT (Quarter) stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then soared by 109.25% to $619000.0 in 2023, then increased by 27.3% to $788000.0 in 2024, then crashed by 1443.15% to -$10.6 million in 2025.
  • Its EBIAT stands at -$10.6 million for Q4 2025, versus $2.0 million for Q3 2025 and -$20.4 million for Q2 2025.